On September 16, Twist Bioscience Corp rose 5.72% in pre-market trading, trading at $146.0 per share, with turnover of $112,000. The rally was driven by upbeat commentary from the company's CEO at the Baird Global Healthcare Conference.

At the conference, the CEO disclosed that fiscal Q4 revenue is expected to reach approximately $124 million, representing roughly 25% year-over-year growth and marking the 15th consecutive quarter of revenue expansion. Notably, AI-related drug discovery orders have already reached $50 million and are projected to double to $100 million next year. This guidance is consistent with the company's earlier Q4 revenue outlook of $123 million to $124 million, which topped the FactSet consensus estimate of $117.4 million issued in early August.

The stock has gained over 50% since August, when Twist Bioscience was selected by Anthropic as an independent experimental service provider for a multi-arm AI protein design project. UBS recently initiated coverage with a Neutral rating and a $144 price target, reflecting growing institutional attention. Despite Q3 EPS of negative $0.56 missing estimates, consecutive revenue beats and the expanding AI pharma pipeline have sustained investor optimism.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)